These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 9787895)
1. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome. Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895 [TBL] [Abstract][Full Text] [Related]
2. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome. Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405 [TBL] [Abstract][Full Text] [Related]
3. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome? Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924 [TBL] [Abstract][Full Text] [Related]
4. Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome. Klarskov K; Gagnon H; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S Toxicol Lett; 2018 Sep; 294():193-204. PubMed ID: 29800716 [TBL] [Abstract][Full Text] [Related]
5. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil]. Maitani T; Saitoh H Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617 [No Abstract] [Full Text] [Related]
6. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome. Silver RM; Sutherland SE; Carreira P; Heyes MP J Rheumatol; 1992 Jan; 19(1):69-73. PubMed ID: 1532618 [TBL] [Abstract][Full Text] [Related]
7. The toxic oil syndrome: 20 years on. Diggle GE Int J Clin Pract; 2001; 55(6):371-5. PubMed ID: 11501225 [TBL] [Abstract][Full Text] [Related]
8. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome. Martínez-Cabot A; Messeguer A Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268 [TBL] [Abstract][Full Text] [Related]
9. The toxic oil syndrome (TOS, 1981): from the disease towards a toxicological understanding of its chemical aetiology and mechanism. Aldridge WN Toxicol Lett; 1992 Dec; 64-65 Spec No():59-70. PubMed ID: 1471212 [TBL] [Abstract][Full Text] [Related]
10. [Toxic oil syndrome--an example of an exogenously-induced autoimmune disease]. Bell S; Brand K; Meurer M Hautarzt; 1992 Jun; 43(6):339-43. PubMed ID: 1628965 [TBL] [Abstract][Full Text] [Related]
11. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622 [TBL] [Abstract][Full Text] [Related]
19. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Klarskov K; Johnson KL; Benson LM; Gleich GJ; Naylor S Adv Exp Med Biol; 1999; 467():461-8. PubMed ID: 10721089 [TBL] [Abstract][Full Text] [Related]
20. Toxic oil syndrome: the perspective after 20 years. Posada de la Paz M; Philen RM; Borda AI Epidemiol Rev; 2001; 23(2):231-47. PubMed ID: 12192735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]